Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

AstraZeneca Announces TAGRISSO Demonstrated Statistically And Clinically Meaningful Improvement In Overall Survival

Positive high-level results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival

Positive high-level results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.

Total
0
Shares
Related Posts